Lyell Immunopharma Inc (LYEL) News & EventsLYELNews & EventsLyell Immunopharma Inc

Lyell Immunopharma Closes $50M Share Sale

Lyell Immunopharma closed the sale of an additional $50M of shares of its common stock to investors from its July 2025 equity private placement of up to $100M, following achievement of a clinical milestone within its PiNACLE pivotal trial evaluating rondecabtagene autoleucel in patients with relapsed/refractory large B-cell lymphoma in the third- or later-line setting. The Company also announced the appointment of Smital Shah as its Chief Financial and Business Officer, effective March 9, 2026. Most recently, she operated as an independent CFO and CBO consultant, providing strategic guidance to multiple life sciences organizations.

Lyell Immunopharma Begins PiNACLE - H2H Phase 3 Trial

Lyell Immunopharma announced that the first patient has been dosed in the PiNACLE - H2H Phase 3 trial evaluating rondecabtagene autoleucel compared to lisocabtagene maraleucel or axicabtagene ciloleucel for the treatment of patients with relapsed or refractory large B-cell lymphoma receiving treatment in the second-line setting. "Data from Lyell's single-arm pivotal PiNACLE trial in patients with later-stage large B-cell lymphoma are expected to be submitted for marketing approval to the FDA next year," said David Shook, MD, Lyell's Chief Medical Officer. "We are now pleased to have underway PiNACLE - H2H, the first-of-its-kind Phase 3 head-to-head randomized controlled CAR T-cell trial. This strategy demonstrates Lyell's confidence in ronde-cel's potential to be the best-in-class CAR T-cell treatment for patients with relapsed or refractory disease."